ADAP Forecast and Technical Stock Analysis
Sell candidate since 2019-12-13 PDF
Adaptimmune Therapeutics plc fell by -1.61% in the last day ( Friday, 13th Dec 2019 ) from $1.24 to $1.22 During the day the stock fluctuated 10.26% from a day low at $1.17 to a day high of $1.29. The price has risen in 6 of the last 10 days and is up by 4.27% over the past 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -243 940 shares and in total 230 769 shares bought and sold for approximately $281 538.00.
- 30 day high of the ADAP stock price was $1.30 and low was $0.71.
- 90 day high was $1.86 and low was $0.71.
- 52 week high for Adaptimmune Therapeutics plc - $6.31 and low - $0.71.
Adaptimmune Therapeutics plc lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $1.23 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -32.23% during the next 3 months and, with 90% probability hold a price between $0.37 and $0.83 at the end of this period.
Adaptimmune Therapeutics plc holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $1.18 and $0.98. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Thursday December 12, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
RSImin/max Values: [ 20 - 75 ]
The stock holds a RSI14 at 77 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
* Stockinvest.us uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behaviour.
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at $1.10 and $1.06.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Adaptimmune Therapeutics plc finds support just below today's level at $1.10. If this is broken, then the next support from accumulated volume will be at $1.06 and $1.01.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.12 between high and low, or 10.26%. For the last week the stock has had a daily average volatility of 10.38%.
The stock is overbought on RSI14 and lies in the upper part of the trend. Normally this may pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.
Our recommended stop-loss: We hold a sell evaluation for this stock. No stop-loss set.
10.38 %Average volatility
Very Low Low Medium High Very High
Adaptimmune Therapeutics plc holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since last evaluation from a Buy Candidate to a Sell Candidate candidate.
|ADAP $1.22 ($-0.02 -1.61%)|
ADAP is down $0.02 today, but where's it headed in 2020?
|Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the ADAP analysis is free »
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!